Having trouble accessing articles? Reset your cache.

Axial: targeting gut microbe metabolites for CNS disorders

Why Axial thinks the gut microbiome is key to Parkinson's disease and autism

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism.

Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the microbiome is driving the disease pathology in these indications from the gut.

The company was founded in 2016 based on research from co-founder Sarkis Mazmanian that indicated gut microbiome manipulation could treat the indications, prompting Longwood Fund, where

Read the full 712 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE